ClinicalTrials.gg
CompletedNCT01600222Updated Mar 7, 2025Results posted

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

A Phase 2 interventional study of LEO 90100 in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 10 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
33rd of 47
37 · median 200
Started
2012
with 3 others
Phase 2
9 of 47
none open now
Registered
23rd of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 33rd largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 23rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.

Read the detailed description

The purpose of the present study is to assess the systemic safety of LEO 90100. Although LEO 90100 contains the same active ingredients in the same concentration as DAIVOBET/DOVOBET/TACLONEX ointment, the degree of absorption of the active ingredients from the new formulation may differ. Systemic safety will be assessed through the effect of LEO 90100 on calcium metabolism and HPA axis function under maximum use conditions (i.e., in subjects with very extensive psoriasis on the trunk, limbs and scalp, using up to 120g per week of LEO 90100 for up to 4 weeks). Data from this study, together with the measurements of albumin-corrected serum calcium and the calcium:creatinine ratio in spot urine samples in the planned phase 2 and 3 studies in the development program for LEO 90100, are expected to provide adequate information with respect to the systemic safety of LEO 90100.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained prior to any trial related activities (including any )
  • Age 18 years or above
  • Either sex
  • Any race or ethnicity
  • Any skin type
  • Attending a hospital out-patient clinic or the private practice of a dermatologist for treatment of psoriasis vulgaris
  • At SV2 and Day 0 (Visit 1), a clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs and the scalp which is;

    • amenable to topical treatment with a maximum of 120g of study medication per week
    • of an extent of between 15 and 30% of the body surface area (BSA) excluding psoriatic lesions of the face, genitals and skin folds
    • including at least 30% scalp involvement
    • of at least a moderate disease severity according to the investigators global assessment (IGA)
  • At SV2, a normal HPA axis function including a serum cortisol concentration above 5 mcg/dl before ACTH-challenge and above 18 mcg/dl 30 minutes after ACTH-challenge
  • At SV2, an albumin-corrected serum calcium below the upper reference range limit
  • At SV2, females of must have a negative urine pregnancy result
  • Females of child-bearing potential must agree to use a highly effective method of during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year)
  • Able to communicate with the investigator and understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • A history of allergic asthma, serious allergy or serious allergic skin rash
  • Known or suspected to component(s) of LEO 90100 or CORTROSYN (including cosyntropin/tetracosactide)
  • Systemic treatment with (including inhaled and nasal steroids) within 12 weeks prior to SV2
  • Systemic treatment with biological therapies (whether marketed or not marketed), with a possible effect on psoriasis vulgaris within the following time period prior to Day 0 (Visit 1);

    • etanercept - within 4 weeks
    • adalimumab, alefacept, infliximab - within 8 weeks
    • ustekinumab - within 16 weeks
    • other products - within 4 weeks/5 half-lives (whichever is longer)
  • Subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to Day 0 (Visit 1)
  • Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. retinoids, methotrexate, cyclosporine and other ) within 4 weeks prior to Day 0 (Visit 1)
  • PUVA therapy within 4 weeks prior to Day 0 (Visit 1)
  • UVB therapy within 2 weeks prior to day 0 (Visit 1).
  • Topical treatment with corticosteroids or vitamin D analogues on any body location within 2 weeks prior to SV2
  • Any topical treatment of psoriasis vulgaris on the trunk, limbs or scalp (except for emollients and non-medicated shampoos) within 2 weeks prior to Day 0 (Visit 1)
  • Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g., betablockers, antimalarials, lithium, ACE inhibitors) during the study
  • Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to SV2. Note: Stable doses of oral vitamin D supplementation ≤400 IU/day is permitted provided there are no dose adjustments during the study period
  • Planned initiation of, or changes to concomitant medication that could affect calcium metabolism (e.g. antacids, thiazide and/or loop diuretics, antiepileptics) during the study
  • Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial sunlight (including tanning booths, sunlamps etc.) during the study
  • Oestrogen therapy (including ), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2
  • Cytochrome P450 3A4 (CYP 3A4) inducers (e.g., barbiturates, phenytoin, rifampicin) within 4 weeks prior to SV2
  • Systemic cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole, itraconazole, metronidazole) within 4 weeks prior to SV2
  • Topical cytochrome P450 3A4 (CYP 3A4) inhibitors (e.g., ketoconazole) within 2 weeks prior to SV2
  • Non-nocturnal sleep patterns (e.g. night shift workers)
  • Any of the following conditions, whether known or suspected:

    • depression and endocrine disorders (e.g. Cushing's disease, Addison's disease, diabetes mellitus) known to affect cortisol levels or HPA axis integrity
    • disorders of calcium metabolism associated with hypercalcaemia
    • cardiac disorders associated with abnormal or rhythm disturbances including bradycardia or tachycardia
    • severe renal insufficiency
    • severe hepatic disorders
  • Any clinically significant abnormality following blood pressure/heart rate measurement or review of screening laboratory tests (blood and spot urine samples) collected at SV2
  • Any clinically significant abnormality following physical examination at SV1
  • Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
  • Any of the following conditions present on the study treatment areas (trunk, limbs and scalp): viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers and wounds
  • Other inflammatory skin disorders (e.g. seborrhoeic dermatitis and contact dermatitis) that may confound the evaluation of psoriasis vulgaris
  • Current participation in any other interventional clinical trial
  • Previously enrolled in this trial
  • Known or suspected of not being able to comply with the trial protocol (e.g., alcoholism, drug dependency or psychotic state)
  • Females who are pregnant, wishing to become pregnant during the study or who are breast-feeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    LEO 90100

    Drug: LEO 90100

Interventions

06

What researchers measure

Primary outcomes

  1. Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)

    HPA-axis testing by means of the rapid standard-dose cosyntropin test (ACTH-challenge test) for detection of adrenal suppression.

    Time frame: Day 28

  2. Change in Albumin-corrected Serum Calcium From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in albumin-corrected serum calcium from Baseline to Day 28.

    Time frame: Baseline and Day 28

  3. Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary calcium excretion from Baseline to Day 28 in 24-hour.

    Time frame: Baseline and Day 28

  4. Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary calcium:creatinine ratio from Baseline to Day 28.

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28

    Serum cortisol concentrations at 30 and 60 minutes after injection were measured in order to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration is ≤18mcg/dl at 30 minutes after the injection.

    Time frame: Day 28

  2. Number of Participants With an Adverse Drug Reaction (ADR)

    Adverse drug reactions (ADRs) were defined as adverse events for which the investigator has not described the causal relationship to investigational medication as "not related".

    Time frame: Baseline to Day 28

  3. Change in Serum Phosphate From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum phosphate from Baseline to Day 28.

    Time frame: Baseline and Day 28

  4. Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary phosphate excretion from Baseline to Day 28.

    Time frame: Baseline and Day 28

  5. Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary phosphate:creatinine ratio from Baseline to Day 28.

    Time frame: Baseline and Day 28

  6. Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum ALP from Baseline to Day 28.

    Time frame: Baseline and Day 28

  7. Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on change in plasma PTH from Baseline to Day 28.

    Time frame: Baseline and Day 28

  8. Change in Blood Pressure From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (blood pressure).

    Time frame: Baseline and Day 28

  9. Change in Heart Rate From Baseline to Day 28

    The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (heart rate).

    Time frame: Baseline and Day 28

  10. Number of Subjects Who Discontinued From the Study

    Number of subjects who discontinued from the study due to adverse events.

    Time frame: Baseline to Day 28

  11. Pharmacokinetic Evaluation Cmax

    The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Cmax are derived from that 1 subject.

    Time frame: 4 weeks / 28 days

  12. Pharmacokinetic Evaluation AUClast

    The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol AUClast are derived from that 1 subject.

    Time frame: 4 weeks / 28 days

  13. Pharmacokinetic Evaluation AUCinf

    The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.

    Time frame: 4 weeks / 28 days

  14. Pharmacokinetic Evaluation Tmax

    The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Tmax are derived from that 1 subject.

    Time frame: 4 weeks / 28 days

  15. Pharmacokinetic Evaluation T1/2

    The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.

    Time frame: 4 weeks / 28 days

  16. Efficacy Evaluation

    The percentage of subjects who achieved 'controlled disease' (i.e., Clear or Almost clear) according to the Investigator's Global Assessment (IGA) of disease severity on the trunk, limbs and scalp at Days 28 (Visit 3) and End of treatment (EoT) were presented.

    Time frame: 4 weeks I 28 days and End of treatment

07

Results

Posted Sep 16, 2016

Participant flow

First Subject First Visit: 4-Jun-2012 Last Subject Last Visit: 2-May-2013

Participant flow — Overall Study
MilestoneLEO 90100
Started37
Completed35
Not completed2

Outcome measures

PrimarySubjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)

HPA-axis testing by means of the rapid standard-dose cosyntropin test (ACTH-challenge test) for detection of adrenal suppression.

Time frame:
Day 28
Reported as:
Number · Subjects
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)
SubjectsLEO 90100
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)0
PrimaryChange in Albumin-corrected Serum Calcium From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in albumin-corrected serum calcium from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/L
Change in Albumin-corrected Serum Calcium From Baseline to Day 28
mmol/LLEO 90100
Change in Albumin-corrected Serum Calcium From Baseline to Day 280.014 ± 0.202
PrimaryChange in 24-hour Urinary Calcium Excretion From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary calcium excretion from Baseline to Day 28 in 24-hour.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/24H
Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28
mmol/24HLEO 90100
Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28-0.49 ± 1.37
PrimaryChange in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary calcium:creatinine ratio from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/g
Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28
mmol/gLEO 90100
Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28-0.0300 ± 1.3997
SecondaryNumber of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28

Serum cortisol concentrations at 30 and 60 minutes after injection were measured in order to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration is ≤18mcg/dl at 30 minutes after the injection.

Time frame:
Day 28
Reported as:
Number · Subjects
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28
SubjectsLEO 90100
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 280
SecondaryNumber of Participants With an Adverse Drug Reaction (ADR)

Adverse drug reactions (ADRs) were defined as adverse events for which the investigator has not described the causal relationship to investigational medication as "not related".

Time frame:
Baseline to Day 28
Reported as:
Number · participants
Number of Participants With an Adverse Drug Reaction (ADR)
participantsLEO 90100
Number of Participants With an Adverse Drug Reaction (ADR)1
SecondaryChange in Serum Phosphate From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum phosphate from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/L
Change in Serum Phosphate From Baseline to Day 28
mmol/LLEO 90100
Change in Serum Phosphate From Baseline to Day 280.030 ± 0.145
SecondaryChange in 24-hour Urinary Phosphate Excretion From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary phosphate excretion from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/24H
Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28
mmol/24HLEO 90100
Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28-0.25 ± 8.67
SecondaryChange in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary phosphate:creatinine ratio from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · mmol/g
Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28
mmol/gLEO 90100
Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 281.847 ± 6.215
SecondaryChange in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum ALP from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · IU/L
Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28
IU/LLEO 90100
Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28-1.5 ± 12.5
SecondaryChange in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on change in plasma PTH from Baseline to Day 28.

Time frame:
Baseline and Day 28
Reported as:
Mean · pmol/L
Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28
pmol/LLEO 90100
Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 280.893 ± 2.207
SecondaryChange in Blood Pressure From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (blood pressure).

Time frame:
Baseline and Day 28
Reported as:
Mean · mmHg
Change in Blood Pressure From Baseline to Day 28
mmHgLEO 90100
Diastolic Blood Pressure (mmHg)-1.5 ± 6.2
Systolic Blood Pressure (mmHg)-2.2 ± 8.1
SecondaryChange in Heart Rate From Baseline to Day 28

The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (heart rate).

Time frame:
Baseline and Day 28
Reported as:
Mean · beats/min
Change in Heart Rate From Baseline to Day 28
beats/minLEO 90100
Change in Heart Rate From Baseline to Day 280.2 ± 10.4
SecondaryNumber of Subjects Who Discontinued From the Study

Number of subjects who discontinued from the study due to adverse events.

Time frame:
Baseline to Day 28
Reported as:
Number · participants
Number of Subjects Who Discontinued From the Study
participantsLEO 90100
Number of Subjects Who Discontinued From the Study0
SecondaryPharmacokinetic Evaluation Cmax

The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Cmax are derived from that 1 subject.

Time frame:
4 weeks / 28 days
Reported as:
Mean · pg/ml
Pharmacokinetic Evaluation Cmax
pg/mlLEO 90100
Betamethasone dipropionate (BDP) (n=5)52.2 (33.7 to 81.1)
betamethasone 17- propionate (n=27)148 (30.2 to 1133)
calcipotriol (n=1)55.9 (55.9 to 55.9)
MC1080 (n=5)24.4 (23.3 to 26.6)
SecondaryPharmacokinetic Evaluation AUClast

The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol AUClast are derived from that 1 subject.

Time frame:
4 weeks / 28 days
Reported as:
Mean · pg/ml
Pharmacokinetic Evaluation AUClast
pg/mlLEO 90100
Betamethasone dipropionate (BDP) (n=5)36.5 (16.9 to 82.5)
betamethasone 17- propionate (n=27)683.6 (18.5 to 4254)
calcipotriol (n=1)82.5 (82.5 to 82.5)
MC1080 (n=5)59.3 (55.3 to 65.5)
SecondaryPharmacokinetic Evaluation AUCinf

The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.

Time frame:
4 weeks / 28 days
Reported as:
Mean · pg/ml
Pharmacokinetic Evaluation AUCinf
pg/mlLEO 90100
Betamethasone dipropionate (BDP) (n=5)NA (NA to NA)
betamethasone 17- propionate (n=27)NA (NA to NA)
calcipotriol (n=1)NA (NA to NA)
MC1080 (n=5)NA (NA to NA)
SecondaryPharmacokinetic Evaluation Tmax

The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Tmax are derived from that 1 subject.

Time frame:
4 weeks / 28 days
Reported as:
Median · h
Pharmacokinetic Evaluation Tmax
hLEO 90100
Betamethasone dipropionate (BDP) (n=5)1.0000 (1.000 to 3.050)
betamethasone 17- propionate (n=27)2.0830 (0.00 to 7.05)
calcipotriol (n=1)2.000 (2.000 to 2.000)
MC1080 (n=5)5.0000 (3.000 to 5.000)
SecondaryPharmacokinetic Evaluation T1/2

The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.

Time frame:
4 weeks / 28 days
Reported as:
Mean · h
Pharmacokinetic Evaluation T1/2
hLEO 90100
Betamethasone dipropionate (BDP) (n=5)NA (NA to NA)
betamethasone 17- propionate (n=27)NA (NA to NA)
calcipotriol (n=1)NA (NA to NA)
MC1080 (n=5)NA (NA to NA)
SecondaryEfficacy Evaluation

The percentage of subjects who achieved 'controlled disease' (i.e., Clear or Almost clear) according to the Investigator's Global Assessment (IGA) of disease severity on the trunk, limbs and scalp at Days 28 (Visit 3) and End of treatment (EoT) were presented.

Time frame:
4 weeks I 28 days and End of treatment
Reported as:
Number · percentage of subjects
Efficacy Evaluation
percentage of subjectsLEO 90100
Day 28 (n=35)48.6
End of treatment (n=37)45.9

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 90100—0/37 (0%)4/37 (10.8%)
Most frequent other events
Most frequent other events
EventLEO 90100
Fungal infectionInfections and infestations1/37
ArthralgiaMusculoskeletal and connective tissue disorders1/37
HeadacheNervous system disorders1/37
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/37
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders1/37
ErythemaSkin and subcutaneous tissue disorders1/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)LEO 90100
Mean48.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)LEO 90100
Female17
Male20
08

Study locations

10 sites
  • Guildford Dermatology Specialists
    Surrey, British Columbia V3R 6A7, Canada
  • PerCuro Clinical Research
    Victoria, British Columbia V8V 3P9, Canada
  • Winnipeg Clinic Dermatology Research
    Winnipeg, Manitoba R3C 0N2, Canada
  • Maritime Medical Research Center
    Bathurst, New Brunswick E2A 4Z9, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • Co-Medica
    Courtice, Ontario L1E 3C3, Canada
  • Mediprobe Research
    London, Ontario N5X 2P1, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Centre de Dermatologie Maizerets
    Quebec City, Quebec G1J 1X7, Canada
09

References and documents

Publications

  • Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. Fixed combination aerosol foam calcipotriene (Cal) 0.005% plus betamethasone 0.064% (as dipropionate; BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Semin Cutan Med Surg. 2015;34 S1:PA-29.
  • Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Semin Cutan Med Surg 2014;33:abst PA-13.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2012
First posted
May 17, 2012
Start
May 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Sep 16, 2016
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01600222
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 17, 2012
Start date
May 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Sep 16, 2016
Last update
Mar 7, 2025

Study contacts

Vicki Taraska
principal investigator · Winnipeg Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion